ALPS Advisors’s Editas Medicine EDIT Stock Holding History

ALPS Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,504	Closed	-$459K	–	1042
2022 Q3	$459K	Sell	37,504 -3,216	-8%	-$50.1K	﹤0.01%	611
2022 Q2	$482K	Buy	+40,720	New	+$546K	﹤0.01%	617

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ALPS Advisors's EDIT Position: Q4 2022 in Review

ALPS Advisors sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 37,504 shares — an estimated $459K sold.

ALPS Advisors first reported a position in EDIT in Q2 2022 and held it in 2 quarters. The position peaked at $482K in Q2 2022. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

ALPS Advisors reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
ALPS Advisors sold 37,504 Editas Medicine shares in Q4 2022, an estimated $459K.
ALPS Advisors first reported a position in Editas Medicine in Q2 2022 and held it in 2 quarters.
ALPS Advisors's Editas Medicine position peaked at $482K in Q2 2022.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.